Business Insights, March 2009, Pages: 168
Parexel 96
Summary 96
Company overview 97
Recent financial performance 97
Performance by business segments 98
Growthstrategies 99
Expansion in emerging markets 99
Acquisitions and divestments 100
SWOT
GBI Research, Feb 2010, Pages: 107
Pharma will Continue to Drive the Drug Discovery Research Market Growth in India and China
The pharmaceutical industries in the US and Europe are facing severe financial constraints which are expected
Datamonitor, Oct 2011, Pages: 135
therapy areas.
Highlights
- In 2010, the women’s health market generated $12bn sales for the top 50 drug companies, accounting for 2.1% of total pharmaceutical sales. Bayer-Schering is the leading player
CYGNUS Business Consulting & Research, Dec 2010, Pages: 248
account for 21%. The strong growth of rural India can also be attributed to strong distribution network. The focus of pharmaceutical marketing has shifted from efficiency to effectiveness. Drug companies
Business Insights, Aug 2009, Pages: 167
the evolving business and relationship models between CROs and sponsor companies and enables optimal outsourcing strategy.
Key features of this report
- Identifies and analyses the most recent trends
MP Advisors, Jan 2011, Pages: 391
' business models. The company capsules' of over 80 bio-pharmaceuticals elucidate the financial and strategic model they follow, the pros and cons about existing and new products, growthstrategies
Aruvian's R'search, Nov 2011, Pages: 285
for entrepreneurial growth is venture capital investments. VC investments have been only growing in India. India today has come to the forefront as a global resource for industry in manufacturing and services. Its
GlobalData, Nov 2010, Pages: 357
revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
- Performing benchmarking analysis and growth opportunities against currently
GlobalData, Nov 2010, Pages: 436
, Russia, India and China
- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
- Competitor assessment including drug launch analysis and drug sales
TriMark Publications, April 2009, Pages: 320
.4.16 Payors Use Biomarkers in Decision-Making 37
2.5 World Pharmaceutical Markets 38
2.5.1 World Market Summary 38
2.5.2 CompanyPerformance in this Segment 40
2.5.3 Forces Affecting the Structure
GlobalData, April 2011, Pages: 335
.4 Hoffmann-La Roche Ltd.
9.4.1 Business Description
9.4.2 Financial Performance
9.4.3 Gastric Cancer Pipeline
9.4.4 SWOT Analysis
9.5 Eli Lilly and Company
9.5.1 Business Description
9.5.2 Financial
